Perrigo Heads for Highest in More Than a Month on FDA Hearing
Perrigo Co. (PRGO) headed for the highest close in six weeks in Tel Aviv as the U.S. Food & Drug Administration is considering rule changes that would allow more prescription drugs to be sold over-the-counter.
The shares of the maker of over-the-counter drugs rose 2.9 percent to 379.50 shekels at 1:56 p.m. in Tel Aviv, poised for the highest close since Jan. 19. The shares have gained 7.5 percent this week.
“It’s definitely an interesting development to see the FDA proactive about switching drugs and not just responding to requests or applications,” said Jonathan Kreizman, analyst at Clal Finance Batucha Brokerage Ltd.
The FDA will hold a public hearing on the matter next month, it said on its website earlier this week.
To contact the reporter on this story: Gwen Ackerman in Jerusalem at firstname.lastname@example.org
To contact the editor responsible for this story: Claudia Maedler at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.